Laure Gossec to Antirheumatic Agents
This is a "connection" page, showing publications Laure Gossec has written about Antirheumatic Agents.
Connection Strength
1.926
-
Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. J Rheumatol. 2019 10; 46(10):1259-1267.
Score: 0.266
-
Fears and beliefs of people living with rheumatoid arthritis: a systematic literature review. Adv Rheumatol. 2018 May 24; 58(1):1.
Score: 0.251
-
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. J Rheumatol. 2018 01; 45(1):6-13.
Score: 0.242
-
Psychometric properties of sleep and coping numeric rating scales in rheumatoid arthritis: a subanalysis of an etanercept trial. Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):786-790.
Score: 0.232
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.077
-
Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. Arthritis Care Res (Hoboken). 2020 12; 72(12):1772-1779.
Score: 0.075
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
Score: 0.072
-
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. J Rheumatol. 2019 08; 46(8):1021-1027.
Score: 0.066
-
Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. J Rheumatol. 2019 08; 46(8):1028-1035.
Score: 0.066
-
Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. Ann Rheum Dis. 2018 12; 77(12):1835-1836.
Score: 0.063
-
Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. Ann Rheum Dis. 2018 08; 77(8):1099-1106.
Score: 0.063
-
The controversy of using PGA to define remission in RA. Nat Rev Rheumatol. 2018 03 21; 14(4):245.
Score: 0.062
-
Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. Arthritis Care Res (Hoboken). 2018 03; 70(3):369-378.
Score: 0.061
-
Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis. 2018 04; 77(4):533-540.
Score: 0.061
-
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. Semin Arthritis Rheum. 2018 04; 47(5):654-665.
Score: 0.060
-
New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017 08 01; 56(8):1251-1253.
Score: 0.059
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun; 76(6):960-977.
Score: 0.058
-
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. J Rheumatol. 2017 Oct; 44(10):1522-1528.
Score: 0.057
-
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
Score: 0.019
-
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2018 06 19; 20(1):129.
Score: 0.016